8-K: BioMarin Closes $850M Senior Notes Offering for Amicus Acquisition

BioMarin Pharmaceutical Inc. has completed a private offering of $850 million in 5.500% Senior Notes due 2034 to finance its pending acquisition of Amicus Therapeutics, Inc. and related credit facilities.

Summary

• BioMarin Pharmaceutical Inc. closed a private offering of $850 million aggregate principal amount of 5.500% Senior Notes due 2034.
• The net proceeds from the Notes offering, along with new senior secured term loan facilities ($2 billion Term Loan B and $800 million Term Loan A) and cash on hand, will fund the acquisition of Amicus Therapeutics, Inc.
• A new $600 million senior secured revolving credit facility is also expected, with up to $150 million potentially borrowed to cover fees and expenses.
• Gross proceeds from the Notes offering were placed into an escrow account, pending the consummation of the Amicus acquisition.
• If the acquisition is not completed by December 19, 2026, or other specified events occur, BioMarin must redeem all Notes at 100% of the issue price plus accrued interest.
• The Notes are jointly and severally guaranteed by certain BioMarin subsidiaries, including Amicus and its subsidiaries after the acquisition closes.
• The Indenture includes covenants restricting additional indebtedness, dividends, restricted payments, liens, asset sales, M&A, and affiliate transactions, with some covenants suspended if the Notes achieve investment grade ratings.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it secures significant financing for a strategic acquisition, indicating growth ambitions and market confidence in BioMarin's ability to execute its strategy. The structured financing with an escrow mechanism mitigates some immediate risks associated with the acquisition's completion.

Positives

• Successfully closed a significant $850 million senior notes offering, demonstrating access to capital markets.
• The financing package, including new credit facilities, provides substantial funding for the strategic acquisition of Amicus Therapeutics, Inc.
• The notes are guaranteed by certain subsidiaries, enhancing security for noteholders.

Negatives

• The notes are subject to a special mandatory redemption if the Amicus acquisition is not completed by December 19, 2026, introducing a contingency for investors.
• The Indenture imposes various covenants that restrict BioMarin's and its subsidiaries' financial and operational flexibility, such as limitations on incurring additional debt, making restricted payments, and asset sales.

Risks

• The acquisition of Amicus Therapeutics, Inc. is pending and may not close, which would trigger a special mandatory redemption of the notes.
• Failure to achieve investment grade ratings could prevent the suspension of certain restrictive covenants, maintaining limitations on the company's financial activities.
• Events of default, including payment defaults, covenant breaches, significant indebtedness acceleration, bankruptcy, or large unpaid judgments, could lead to acceleration of the notes.
• Fluctuations in currency exchange rates could impact the U.S. dollar-equivalent principal amount of foreign currency-denominated indebtedness.

Future Outlook

BioMarin intends to use the proceeds from this notes offering and new credit facilities to fund the pending acquisition of Amicus Therapeutics, Inc. The company expects to enter into additional senior secured credit facilities in connection with this acquisition. The notes are subject to a special mandatory redemption if the acquisition is not completed by December 19, 2026.

Management Comments

• BioMarin Pharmaceutical Inc. announced the closing of its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034.

Industry Context

StockSavvy.ai notes that this debt issuance and planned acquisition of Amicus Therapeutics, Inc. positions BioMarin to expand its portfolio within the rare disease biotechnology sector. This move aligns with a broader industry trend of consolidation and strategic M&A activity among pharmaceutical companies seeking to enhance their pipelines and market presence in specialized therapeutic areas. The financing structure, combining senior notes with secured term loans, is a common approach for funding significant corporate acquisitions, reflecting market confidence in BioMarin's strategic direction and ability to manage increased leverage.

Comparison to Industry Standards

• The 5.500% interest rate on the senior notes due 2034 is competitive for a company in the biotechnology sector, reflecting current market conditions for corporate debt and BioMarin's credit profile.
• The use of a combination of senior notes and secured term loans for acquisition financing is a standard practice in the pharmaceutical industry, similar to recent financing strategies employed by companies like AbbVie for its Allergan acquisition or Bristol Myers Squibb for Celgene, albeit on a smaller scale.
• The covenants outlined in the Indenture, such as the Fixed Charge Coverage Ratio (2.00 to 1.00) and Consolidated Total Net Leverage Ratio (3.25 to 1.00), are within typical ranges for high-yield or crossover credit quality debt in the biotech and pharmaceutical sectors, providing standard protections for noteholders while allowing operational flexibility.

Corporate Governance

Related Party Transactions

• The Indenture includes provisions for transactions with affiliates, requiring them to be on terms no less favorable than those with unrelated persons for transactions exceeding $75 million, and requiring Board of Directors approval for transactions exceeding $150 million.

Stakeholder Impact

• Shareholders: The debt issuance and acquisition could lead to long-term growth and value creation if the acquisition is successful, but also introduces increased leverage and potential dilution if equity is used for future capital raises.
• Noteholders: The notes provide a fixed income stream with guarantees from subsidiaries, but carry the risk of special mandatory redemption if the acquisition fails, and are subject to various covenants.
• Employees: The acquisition of Amicus Therapeutics, Inc. could lead to integration efforts and potential changes in organizational structure, but also opportunities for growth within an expanded company.
• Customers: The acquisition aims to expand BioMarin's product portfolio, potentially offering a broader range of therapies for genetically defined conditions.
• Creditors: The new debt increases BioMarin's overall leverage, which could impact its credit profile and ability to incur future debt.

Next Steps

• Consummation of the pending acquisition of Amicus Therapeutics, Inc.
• Entry into the new $2 billion senior secured term loan B facility and $800 million senior secured term loan A facility.
• Entry into the $600 million senior secured revolving credit facility.
• Potential borrowing of up to $150 million under the new revolving facility to pay fees and expenses related to the acquisition and financing.

Key Dates

Keywords

Senior Notes, Debt Offering, Acquisition Financing, Amicus Therapeutics, BioMarin Pharmaceutical, SEC Filing, Corporate Bonds, Credit Facilities, Escrow, Covenants, Corporate Governance